Inactive Instrument

Highlights GRI Bio, Inc.

Equities

GRI

US3622AW2059

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
0.4007 ^USD	-1.18%		+2.72%	-85.13%

05-21	GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	CI
05-20	GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	05-21	CI
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	05-20	CI
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	04-16	CI
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	03-04	CI
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	01-26	MT
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	12-05	CI
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	11-27	CI
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
GRI Bio, Inc. completed the acquisition of Vallon Pharmaceuticals, Inc. from group of shareholders in a reverse merger transaction.	23-04-20	CI
GRI Bio, Inc. entered into a definitive agreement to acquire Vallon Pharmaceuticals, Inc. from group of shareholders for $49 million in a reverse merger transaction.	22-12-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer